Redeye provides its initial take on MedCap’s Q1 2025 report, which broadly aligned with our estimate...
Redeye provides an update following Nitro Games’ Q1 2025 report, which was in line with expectations...
Redeye changes its Base Case and forecasts following a mixed Q1 report from Addnode.
Minor negative revisions following Q1 report Earnings growth of ~40% in '25e Trading ~20% below sect...
Vid en första anblick såg Vaxxas rapport svag ut med totala intäkter om cirka 13 MSEK och en bruttom...
NOI +75% y-o-y and -0.7% vs ABGSCe Value uplift 2.1% q-o-q, net LTV at 48.
Redeye comments on Kardium's 1-year study results for its CHS-coated Globe system.
Stark försäljningsstart med blandad utveckling Acuvi vände trenden och visade försäljningstillväxt e...
Fastpartners hyresintäkter och driftnetto minskade något för det första kvartalet drivet av avyttrin...
The company’s reported EBITDA was EUR 21m (Nordea est.
Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025.
Alternative MRI contrast agent for frail cancer patients Ph 3 finished and ready for FDA filing Init...
The start of 2025 was weaker than market consensus (LSEG) expected.
Redeye maintains a positive view on Dynavox, which delivered another quarter of impressive growth, w...
Redeye updates its estimates and valuation following the Q1 2025 report from Safeture.
